Placebo News and Research

RSS

Two new TB vaccines show safety but limited protection

Two new vaccines to prevent tuberculosis (TB) are safe for use in adults and children, but they do not offer protection against all forms of TB, finds a large trial from India published by The BMJ today.

9 Apr 2026

New monoclonal antibody shows promise for preventing Lyme disease

A Phase I clinical trial of a human monoclonal antibody discovered and developed at UMass Chan Medical School for the prevention of Lyme disease in the U.S. was well tolerated and showed lasting serum concentrations in participants, according to data presented by Mark Klempner, MD, at the World Vaccine Congress 2026 in Washington D.C.

8 Apr 2026

Crisis-driven maternal psychological stress can affect fetal development and birth outcomes

Fetal development is a critical stage with effects that can last throughout life. Yet, identifying the effects of maternal psychological stress on the fetus has been difficult, mainly because stressful events often produce psychological and physical consequences that directly affect mothers and their children.

8 Apr 2026

Duloxetine fails to prevent nerve damage caused by chemotherapy

A randomized trial conducted by the Alliance for Clinical Trials in Oncology with support from the National Cancer Institute has found that duloxetine, a medication commonly used to treat chronic pain and psychiatric conditions, does not prevent nerve damage caused by chemotherapy in patients with colorectal cancer.

8 Apr 2026

Hearing loss and sex shape dual-task outcomes in older adults with mild cognitive impairment

Cognitive and physical training can help older adults with mild cognitive impairment (MCI) maintain or improve their ability to move and think simultaneously, but hearing ability and sex influence outcomes, according to a new Concordia-led study.

7 Apr 2026

What happens in the brain on psychedelics? Scientists identify a common circuit pattern

Researchers combined 11 international resting-state fMRI datasets to map how psychedelic drugs reshape brain connectivity across cortical and subcortical circuits. The mega-analysis found a shared signature of stronger coupling between transmodal association networks and unimodal or sensorimotor systems, alongside selective and variable reductions in within-network connectivity.

7 Apr 2026

Evolocumab trial could reshape how doctors treat high-risk cholesterol patients

A new ACC/AHA dyslipidemia guideline and editorial argue that guideline development is rigorous but can lag behind fast-moving science, using the VESALIUS-CV trial as a clear example. The trial showed that intensive LDL cholesterol lowering with evolocumab reduced cardiovascular events in high-risk patients without prior heart attack or stroke, with implications for future guideline updates.

6 Apr 2026

Wegovy® (semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events, including heart attacks and strokes, in adults with established cardiovascular disease and overweight or obesity (BMI ≥ 27 kg/m2)

NICE has recommended Wegovy® (semaglutide injection) 2.4 mg as the first GLP-1 RA to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI ≥ 27 kg/m2).

From Novo Nordisk 2 Apr 2026

Kinesio taping offers limited benefits for treating musculoskeletal pain and mobility

Kinesio taping, or 'KT tape' as it's usually known-widely used to ease joint/muscle pain and boost range of movement-may not be all that effective, suggests a pooled data analysis of the existing evidence, published in the online journal BMJ Evidence Based Medicine.

1 Apr 2026

Treating autonomic dysfunction can relieve symptoms of treatment-resistant depression

Consider a house with the water main half shut. The faucets sputter. The toilet runs all night. The garden wilts. You could call a plumber for the faucet, a landscaper for the garden, a different plumber for the toilet, and every one of them would fix something while fixing nothing.

31 Mar 2026

Why vaginal microbiota transplants aren’t working yet

Vaginal microbiota transplantation without antibiotics fails to restore microbiome balance, yet engraftment suggests avenues for enhancing treatment efficacy.

31 Mar 2026

Vaping beats traditional tools for quitting smoking

The review indicates nicotine e-cigarettes could surpass traditional quit aids in effectiveness, but lingering safety uncertainties warrant further research.

31 Mar 2026

Antidepressant fluvoxamine reduces long COVID fatigue in clinical trial

A randomized placebo-controlled trial found that fluvoxamine, a low-cost antidepressant, reduced fatigue and improved quality of life in adults with long COVID, offering one of the first evidence-based medication options for this persistent condition. In contrast, metformin did not provide meaningful benefit for established long COVID fatigue, highlighting fluvoxamine as the more promising treatment candidate in this study.

30 Mar 2026

Triglyceride-lowering drug olezarsen fails to reduce arterial plaque

Despite experiencing significant reductions in triglycerides, patients with triglycerides over 150 mg/dL and a high risk of atherosclerosis did not experience any significant change in the amount of non-calcified plaque in their coronary arteries after taking the triglyceride-lowering drug olezarsen, in a one-year sub-study presented at the American College of Cardiology's Annual Scientific Session.

30 Mar 2026

Digoxin found safe to use in young patients with rheumatic heart disease

Patients with rheumatic heart disease who took the heart failure drug digoxin were 18% less likely to die or experience new-onset or worsening heart failure during a two-year follow-up compared with those who received a placebo, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

30 Mar 2026

Taking a placebo knowingly still improves stress and memory

Research indicates open-label placebos can ease stress and boost memory in older adults, presenting a novel, ethical strategy for promoting healthy aging.

30 Mar 2026

New drug sotatercept shows benefit in CpcPH-HFpEF patients

Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary hypertension) experienced significant improvements in blood pressure and vascular health after taking the drug sotatercept, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

Trial shows mavacamten benefits adolescents with obstructive heart condition

Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant improvement in left ventricular outflow tract (LVOT) gradient, a measure of blood flow obstruction in the heart, compared with those who received a placebo, according to a small study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

Angioplasty improves symptoms in chronic total coronary occlusion patients

In what is believed to be the first randomized placebo-controlled trial of its kind, patients with a chronic total blockage of a coronary artery who received a nonsurgical procedure to reopen the artery showed statistically significant reductions in chest pain and improvements in quality of life compared with patients who received a placebo procedure.

29 Mar 2026

Evolocumab reduces cardiac events in high-risk diabetic patients

The cholesterol-lowering therapy evolocumab reduced the risk of major adverse cardiac events by nearly one-third among patients who had no known significant atherosclerosis and had diabetes, according to a study presented at the American College of Cardiology's Annual Scientific Session.

28 Mar 2026